J&J CFO Joseph Wolk told the Journal various jobs could be affected but it wouldn’t be a big layoff.
“We’re not immune to some of the economic pressures that are out there just like many companies are facing in many industries,” Mr. Wolk told the Journal. “So we’re taking this opportunity to really look at the resources, how we deploy them.”
J&J announced the consumer health spinoff in November 2021 and has since chosen some of its top executives and named it Kenvue. The pharmaceutical company plans the split to happen in mid- to late 2023.
The news followed the drugmaker’s third-quarter report, which showed a higher revenue compared to last year — $4.46 billion, a step up from $3.67 billion in 2021.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.